Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urethelium.

Trial Profile

Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urethelium.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 06 Aug 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 01 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top